Drug data last refreshed 17h ago · AI intelligence enriched 6d ago
Zoloft (sertraline hydrochloride) is a selective serotonin reuptake inhibitor (SSRI) approved in 1991 for depression, anxiety, OCD, PTSD, panic disorder, and premenstrual dysphoric disorder. It works by increasing serotonin availability in the brain by blocking reuptake at the synaptic level.
Zoloft is in advanced lifecycle stage with high competitive pressure (60/100), signaling smaller brand teams focused on generic defense and value positioning rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Relative Bioavailability Study of Zoloft Oral Solution to Zoloft Tablets
Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects
A Study Comparing the Drug Exposure in Humans After Administration of a 50 mg Tablet of Sertraline Hydrochloride as Compared to a 50 mg Capsule of Sertraline Hydrochloride Under Fasted (Nonfed) Conditions
Drug Use Investigation of Jzoloft.
Special Investigation Of J Zoloft For Panic Disorder Patients
Worked on ZOLOFT at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Zoloft in the LOE-approaching phase offers limited growth trajectory but deep expertise in mature product management, generic defense, and payer negotiations. Career advancement on this product is incremental; professionals often transition to newer launches or pipeline assets after proving competency in mature market dynamics.